Outcomes of Deucrictibant-Treated Upper Airway and Laryngeal Hereditary Angioedema Attacks: RAPIDe-2 Part A Results

John Anderson[1], Emel Aygören-Pürsün[2], Henriette Farkas[3], Joshua S. Jacobs[4], Michael E. Manning[5], Anna Valerieva[6], Giorgio Giannattasio[7*], Yumeng Li[8], Ming Yu[8*], Marc A. Riedl[9]

[1]AllerVie Health, Clinical Research Center of Alabama, Birmingham, AL, USA; [2]University Hospital Frankfurt, Goethe University Frankfurt, Department for Children and Adolescents, Frankfurt, Germany; [3]Hungarian Angioedema Center of Reference and Excellence, Department of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary; [4]Allergy and Asthma Clinical Research, Walnut Creek, CA, USA; [5]Allergy, Asthma and Immunology Associates, Ltd., Scottsdale, AZ, USA; [6]Medical University of Sofia, Department of Allergology, Sofia, Bulgaria; [7]Pharvaris Inc., Zug, Switzerland; [8]Pharvaris Inc., Lexington, MA, USA; [9]University of California San Diego, Division of Allergy and Immunology, La Jolla, CA, USA

Key takeaways

The final data from Part A of the RAPIDe-2 study provide evidence that safety and efficacy outcomes of treatment with deucrictibant immediate-release (IR) capsule were consistent for both hereditary angioedema (HAE) attacks affecting the upper airways, including laryngeal attacks, and HAE attacks occurring in other locations.

Safety

- No treatment-related TEAEs across upper airway and non-upper airway attacks

Efficacy

- **1.4 Hours** — Median time to onset of symptom relief for upper airway attacks
- Similar median times to symptom relief and resolution for upper airway attacks and other attacks
- **92.9%** of upper airway attacks were treated with a single dose of deucrictibant IR capsule

IR, immediate-release; TEAEs, treatment-emergent adverse events.

Background

- **Hereditary angioedema (HAE):** a bradykinin-mediated condition with painful swelling attacks affecting multiple locations in the body and potentially life-threatening when airways, including the larynx, are involved.[1-4]
- **Unmet need:** guidelines recommend HAE attacks are treated as early as possible.[2-4] Parenteral administration often leads to on-demand treatment of HAE attacks being delayed or forgone.[5-9]
- **Deucrictibant:** a selective, investigational, orally administered, bradykinin B2 receptor antagonist under development for both prophylactic and on-demand treatment of HAE attacks.[10-17]

Objective

Evaluate the safety and efficacy of deucrictibant immediate-release (IR) capsule for on-demand treatment of upper airway, including laryngeal, HAE attacks.

Methods

- **RAPIDe-2 (NCT05396105)*:** a two-part, Phase 2/3 long-term extension study.[12]
- **Part A eligible participants:** adults who completed RAPIDe-1 (NCT04618211).[10]
- **Part A prophylaxis:** no long-term HAE prophylaxis treatment was allowed. Recent use of long-term HAE prophylaxis treatment prior to screening was allowed provided a pre-specified washout period was observed.

Figure 1. RAPIDe-2 study design



IR, immediate-release.

Methods

- **Primary endpoint:** safety, including treatment-emergent adverse events (TEAEs), clinical laboratory tests, vital signs, and electrocardiogram (ECG) findings.
- **Secondary endpoints:** efficacy endpoints assessed using patient-reported outcome tools.
- **Data collection:** pre-specified at pre-treatment, hourly for 6 hours, and at 8, 12, 24, and 48 hours post-treatment.

Figure 2. Efficacy assessment scales



Table 1. Efficacy endpoints

Key efficacy endpoints included	Defined as
Time to and proportion of attacks achieving	
Onset of symptom relief	PGI-C rating of at least "a little better" for 2 consecutive timepoints by 12 hours[a]
Substantial symptom relief	PGI-C rating of at least "better" for 2 consecutive timepoints by 12 hours[a]
Reduction in attack severity	≥1-level reduction in PGI-S from pre-treatment for 2 consecutive timepoints by 12 hours[b]
Complete attack resolution	PGI-S rating of "none" within 48 hours for time-to-event analysis PGI-S rating of "none" at 24 hours for proportion analysis

PGI-C, Patient Global Impression of Change; PGI-S, Patient Global Impression of Severity. [a]If rescue medication used within 14.5 hours post-treatment, time to event was censored at 14.5 hours regardless of whether event occurred within 12 hours post-treatment. [b]Rescue medication use within 33.5 hours post-treatment was regarded as not achieving complete attack resolution at 24 hours.

- **Post hoc analysis:** safety and efficacy for on-demand treatment of upper airway attacks, including laryngeal attacks without breathing difficulties.
  - Upper airway attacks confirmed by investigators as per protocol definition if following manifestations of an attack were reported: swelling of the lips/tongue or any sensation of lump in the throat, difficulty swallowing, or voice change.
  - Difficulty swallowing and voice change as manifestations of an attack were assessed prior to treatment using the 5-symptom composite Angioedema syMptom Rating scAle (AMRA-5).
  - AMRA-5 is a numeric rating scale derived from the visual analog scale (VAS) to assess symptoms of HAE attacks.[19]

Results

Data

- Final combined dose group data from RAPIDe-2 Part A.

Attacks

- 465 attacks were treated by 19 participants.
  - 14 upper airway attacks, including laryngeal, were treated for seven participants.
  - Difficulty in swallowing and/or voice change were reported as manifestations of six attacks prior to treatment.

Table 2. Baseline characteristics of participants with and without upper airway attacks

Characteristics	Participants with ≥1 upper airway attacks (n=7)[a]	Participants without upper airway attacks (n=12)[a]
Age in years, mean (SD)	46.0 (19.5)	43.4 (17.2)
Sex: Male / female, n (%)	4 (57) / 3 (43)	3 (25) / 9 (75)
Race: White / other, n	7 / 0	11 / 1
BMI, mean (SD)	27.1 (3.8)	26.7 (4.2)
Years since HAE diagnosis, mean (SD)	20.8 (18.9)	24.7 (13.3)
HAE type, n (%)		
HAE-1	6 (85.7)	11 (91.7)
HAE-2	1 (14.3)	1 (8.3)

BMI, body mass index; HAE, hereditary angioedema; SD, standard deviation. n=number of participants. [a]All participants who received any dose of deucrictibant in the study. Study baseline refers to results at the screening or enrollment visit of RAPIDe-2 Part A. For parameters whose values remain constant over time, baseline values from RAPIDe-1 were used. For parameters without results at the screening or enrollment visit of RAPIDe-2 or for parameters not collected at that time, the last available assessment in RAPIDe-1 was used as the baseline values.

Safety analysis

- Deucrictibant was generally well tolerated with no treatment-related TEAEs reported across upper airway and non-upper airway attacks.

Efficacy analysis

Table 3. Similar times to symptom relief and resolution for upper airway and non-upper airway attacks

	Upper airway attacks (n=7)	Non-upper airway attacks in participants with upper airway attacks (n=7)	Total non-upper airway attacks (n=19)
Total number of attacks treated[a]	14	177	451
Time to onset of symptom relief[b]			
Number of attacks[c]	14	171	443
Median hours (95% CI)	**1.4** (0.8–3.0)	**1.0** (1.0–1.2)	**1.1** (1.0–1.1)
Time to substantial symptom relief[b]			
Number of attacks[c]	14	171	443
Median hours (95% CI)	**3.6** (2.0–6.1)	**2.7** (2.1–3.0)	**2.4** (2.1–2.8)
Time to reduction in attack severity[b]			
Number of attacks[d]	12	169	437
Median hours (95% CI)	**1.8** (0.9–3.0)	**2.1** (2.0–2.8)	**2.8** (2.4–2.9)
Time to complete attack resolution[b]			
Number of attacks[d]	12	169	437
Median hours (95% CI)	**8.9** (3.9–36.3)	**8.0** (7.3–10.7)	**10.6** (8.5–11.5)

CI, confidence interval; PGI-C, Patient Global Impression of Change; PGI-S, Patient Global Impression of Severity. [a]465 attacks treated by 19 participants. [b]Within-participant correlation not accounted for in all Kaplan–Meier estimates. [c]Evaluable attacks include deucrictibant-treated attacks with ≥1 post-treatment PGI-C assessment. [d]Evaluable attacks included deucrictibant-treated attacks with a pre- and ≥1 post-treatment PGI-S assessment.

Results

Figure 3. Majority of upper airway attacks achieved key efficacy endpoints



PGI-C, Patient Global Impression of Change; PGI-S, Patient Global Impression of Severity. [a]Evaluable attacks include deucrictibant-treated attacks with ≥1 post-treatment PGI-C assessment. [b]Evaluable attacks were study-drug-treated attacks with both a pre- and post-treatment PGI-S result. [c]Defined as achieving PGI-S rating of "none" at the last available timepoint before or at 24 hours post-treatment without use of rescue medication.

Figure 4. Majority of upper airway attacks were treated with a single dose of deucrictibant within 24 hours



IR, immediate-release. [a]For non-upper airway attacks, a second dose permitted ≥4 hours after first dose if symptoms persisted or progressed. If symptoms persisted or progressed after the second dose, rescue medication was administered. For upper airway attacks with inadequate response or symptom recurrence ≥4 hours after first dose, only rescue medication was permitted. [b]One participant used rescue medication for one upper airway attack and used a single dose of deucrictibant to treat 2 subsequent upper airway attacks.

Figure 5. Majority of upper airway attacks did not use rescue medication within 24 hours



[a]For non-upper airway attacks, a second dose permitted ≥4 hours after first dose if symptoms persisted or progressed. If symptoms still persisted or progressed after the second dose, rescue medication was administered. For upper airway attacks with inadequate response or symptom recurrence ≥4 hours after first dose, only rescue medication was permitted. [b]One participant used rescue medication for one upper airway attack and used a single dose of deucrictibant to treat 2 subsequent upper airway attacks.

This presentation includes data for an investigational product not yet approved by regulatory authorities.

References

1. Busse PJ, et al. *N Engl J Med*. 2020;382:1136-48. 2. Betschel S, et al. *Allergy Asthma Clin Immunol*. 2019;15:72. 3. Busse PJ, et al. *J Allergy Clin Immunol Pract*. 2021;9:132-50. 4. Maurer M, et al. *Allergy*. 2022;77:1961-90. 5. Center for Biologics Evaluation and Research. The voice of the patient–hereditary angioedema. US Food and Drug Administration; May 2018. https://www.fda.gov/media/113509/download. Accessed September 22, 2025. 6. Betschel SD, et al. *Allergy Asthma Clin Immunol*. 2024;20:43. 7. Covella B, et al. *Future Pharmacol*. 2024;4:41-53. 8. Christiansen S, et al. *Ann Allergy Asthma Immunol*. 2025;134(5):570-579. 9. Mendivil J, et al. Presented at: ACAAI; November 9–13, 2023; Anaheim, CA, USA. 10. RAPIDe-1. https://www.clinicaltrials.gov/study/NCT04618211. Accessed September 22, 2025. 11. Maurer M, et al. Presented at: AAAAI; February 24–27, 2023; San Antonio, TX, USA. 12. RAPIDe-2. https://www.clinicaltrials.gov/study/NCT05396105. Accessed September 22, 2025. 13. RAPIDe-3. https://www.clinicaltrials.gov/study/NCT06343779. Accessed September 22, 2025. 14. CHAPTER-1. https://www.clinicaltrials.gov/study/ NCT05047185. Accessed May 20, 2025. 15. CHAPTER-3. https://clinicaltrials.gov/study/NCT06669754. Accessed September 22, 2025. 16. CHAPTER-4. https://clinicaltrials.gov/study/NCT06679881. Accessed September 22, 2025. 17. Aygören-Pürsün E, et al. Presented at: EAACI; May 31–June 3, 2024; Valencia, Spain. 18. Cohn DM, et al. *Clin Transl Allergy*. 2023;e12288. 19. Mendivil J, et al. Presented at: UCARE; December 7–9, 2023; Sao Paulo, Brazil.

COI: J.A.: BioCryst, BioMarin, CSL Behring, Cycle Pharma, KalVista, Pharming, Pharvaris, Takeda. **E.A-P.:** Astria, BioCryst, CSL Behring, Intellia, KalVista, Otsuka, Pharvaris, Takeda. **H.F.:** BioCryst, CSL Behring, Intellia, KalVista, ONO Pharmaceutical, Pharming, Pharvaris, Takeda. **J.S.J.:** BioCryst, CSL Behring, Cycle Pharma, Oasis, Pharming, Pharvaris, Takeda. **M.E.M.:** Allakos, Amgen, AstraZeneca, BioCryst, Blueprint, CSL Behring, Cycle Pharma, Genentech, GSK, KalVista, Merck, Novartis, Pharming, Pharvaris, Sanofi/Regeneron, Takeda. **A.V.:** AstraZeneca, Berlin-Chemie/Menarini Group, CSL Behring, KalVista, Novartis, Pharming, Pharvaris, Sobi, Takeda. **G.G., Y.L., M.Y.:** Employees of Pharvaris, hold stocks in Pharvaris. **M.A.R.:** Astria, BioCryst, BioMarin, Celldex, CSL Behring, Cycle Pharma, Grifols, Intellia, Ionis, KalVista, Novartis, Pharming, Pharvaris, Sanofi-Regeneron, Takeda.
Acknowledgments: Medical writing services were provided by Holly Richendrfer, PhD, CMPP, of Envision Spark, an Envision Medical Communications agency, a part of Envision Pharma Group and funded by Pharvaris Netherlands B.V.

RAPIDe-2 is a Pharvaris-sponsored clinical study. ClinicalTrials.gov identifier: NCT05396105.